Eli Lilly’s orforglipron, marketed as Foundayo, cleared the FDA on Wednesday under the agency’s commissioner’s voucher program, positioning the once-injectable GLP-1 class for a fresh competitive push. The approval sets up direct head-to-head pressure against Novo Nordisk’s Wegovy, as more patients and payers explore oral alternatives to weekly injections. The decision also places Lilly in the market transition from first-generation incretin products toward differentiated oral options that may be easier for patients to adopt. With orals typically delivering less weight loss on average than injections, the competitive question is whether dosing convenience can translate into sustained share. Lilly’s approval arrives as the oral segment expands across the obesity landscape, with developers increasingly betting that oral small molecules can be combined with other therapies and broaden usage beyond injection-averse patients.